DRD and DRID annual expert meeting, 14-17 October 2014
Belgium
Bulgaria
Expert meeting on drug-related harms and responses,
14–17 October 2014, Lisbon
DRD drug-related deaths (DRD) and Drug-related infectious diseases (DRID) key epidemiological indicators annual expert meetings, and satellite event on naloxone
The DRD/DRID key epidemiological indicators expert meetings was this year again implemented in an integrated format, with some joint sessions. This year, among other topics, the focus was on evidence from overdose and toxicology, mortality cohort studies, cannabis-related emergencies, HCV infections and treatment, HIV outbreaks among drug users, changing and new groups of injectors, emerging risks. There were technical workshops and ‘conference-like’ plenaries. Attendance in the expert meetings was restricted to nominated experts of the 28 EU Member States, Norway and Turkey, and invited speakers. Our EU partners, international organisations and non EU countries were represented.
The DRD/DRID meetings was preceded by a half-day satellite event entitled Take home naloxone to reduce fatalities: scaling up a participatory intervention across Europe, which was open to interested participants who were not in the respective EMCDDA expert networks.
Registration and practical information
The event took place at the EMCDDA’s Conference Centre in Lisbon, Portugal, starting on Tuesday, 14 October 2014 and ending on Friday, 17 October (see agenda on the right). A call for input to the DRD/DRID meeting was sent to the expert networks and proposals for input and abstracts could be submitted until 31 August 2014 (see templates on the side).
Please use the DRD-DRID-2014@emcdda.europa.eu for any communication related to the event.
Key documents:
- Agenda
- Call for abstracts, DRD
- Call for abstracts, DRID
- Compilation National Abstracts DRD 2014
- Compilation National Abstracts DRID 2014
- Meeting Report - Highlights
Presentations:
Session 1: Introduction to the meeting, most recent national data and a focus on Nordic countries
- Discussion of most recent key indicator and national developments: Fonte reports 2014 - Isabelle Giraudon, EMCDDA
- On-going increase of overdose deaths: contribution of polydrug use - Anna Fugelstad, Sweden
- Opioid dependence and treatment for the 21st century: Norwegian national overdose prevention strategy - Thomas Clausen, Norway
- Pregabalin and gabapentin in opioid overdose deaths - Ilkka Ojanperä, Finland
- EU-MADNESS project on NPS: objectives and expected outcomes, with a special focus on methodologies in respect of NPS-related deaths - John Corkery, United Kingdom
- Povidone/Marindale methadone case - Thomas Clause, Norway
Session 2A: Implications of benzodiazepine in drug-related deaths
- Scottish Blues: The role of benzodiazepines in drugrelated deaths in Scotland - Saket Priyadarshi, United Kingdom
- Impact of Benzodiazepines on DRD in Ireland - Ena Lynn, Ireland
- Analyses of the special mortality register data (DRAMES) - Michel Mallaret, France
- Update of Instituto Nacional de Medicina Legal e Ciências Forenses - Mario Dias, Portugal
- Update on BZD from Hjelt Institute, Department of Forensic Medicine - Ilkka Ojanperä, Finland
Session 2B: Mortality cohort studies among drug users
- Results of national mortality cohort study followed up to 2012 - Janusz Sieroslawski, Poland
- A record-linkage study of opioid-related deaths and treatment for opioid misuse in England in 2008–11 - Martin White, United Kingdom
- Cohort study in Central Asia (brief presentation) and database-linkage study among gamblers - Viktor Mravcik, Czech Republic
- Assessing the gender effect in mortality risk and excess mortality from natural and external causes among heroin or cocaine users in Spain - Gregorio Barrio and Gemma Molist, Spain
- Cardiovascular diseases as underlying cause of death among treated drug users - Jozica Selb, Slovenia
Session 3: DRD related to heroin and to methadone
- Deaths due to intravenous methadone use in Hamburg – using toxicological method to get information on the route of administration - Axel Heinemann, Germany
- Poisoning deaths where methadone was implicated - Ena Lynn, Ireland
- Overview of deaths among drug addicts with focus on methadone-related deaths - Tanja Coric, Croatia
- Dramatic increase in DRD numbers compared to last year: heroin in cause? Review, analysis and implications - Bulent Sam, Turkey
- Why have heroin-related deaths rebounded in England? An insight from the GMR and SMR sources — John Corkery, United Kingdom
Session 4: Cannabis-related emergencies and harm
- Key note speech on the adverse health effects of cannabis - Wayne Hall, Australia
- Emergency Department Presentations with Acute Cannabis Toxicity in Europe: Data from the Euro-DEN Project — David Wood, United Kingdom
- An update on cannabis: multi-indicator insight — Elena Alvarez, Spain
- Review of some European national data on cannabis-related emergencies: strengths, limitations, public health implications - Marcis Trapencieris, Latvia
- A drug treatment programme for young backpackers with psychosis due to cannabis abuse - Haim Mell, Israel
Session 5: High overdose mortality and HIV rates: multi-indicator insight on epidemiology and responses in Latvia and Estonia
- Drug overdose mortality in Estonia: toxicology, trends, role of fentanyls in drug-induced deaths - Gleb Denissov, Estonia
- Underestimation of overdose deaths in Latvia: an insight from coding of deaths in mortality cohort studies - Ildze Redoviča & Marcis Trapencieris, Latvia
- Improvements in the linkage between DRID and TDI in Latvia - Anda Karnite, Latvia
- Feedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA to Latvia in September 2014 - Nicole Werner Keiss, Latvia
Session 6: Tackling HCV: morbidity, access to new treatments, treatment as prevention
- Hepatitis C treatment and prevention among people who inject drugs: Epidemiology and economic modelling for viral elimination - Matthew Hickman, United Kingdom
- Hepatitis B and C trends in EU/EEA - Andrew Amato, United Kingdom
- Hepatitis Plus (Correlation) Access to HCV treatment: a European multisite study - Heike Zurhold, Germany
- An hepatologist perspective of HCV infection in Portugal - Rui Tato Marinho, Portugal
- Multisite prevalence study 2014 among injectors and non injectors - Janusz Sieroslawski, Poland
- Concerns with 2014 increasing HCV prevalence - Gergely
Horvath, Hungary
Session 7: Setting the scene / Introduction and update
- Presentation/discussion of some recent reported national developments - Isabelle Giraudon, EMCDDA
- Injecting drug use and HIV, HBV and HCV. Preliminary results from the ‘DRUCK-study’ - Ruth Zimmermann, RKI, Germany
- Mephedrone injecting risks and infections in the United Kingdom - Vivian Hope, United Kingdom
- Late breaking communications: Botulism outbreak - Hans Blystad, Norway
Session 8A: Using behavioural data and data from NSPs to target prevention responses
- DRUCK-study - Ruth Zimmermann, Germany
- Overview of behavioural surveillance data - Eleni Kalamara, EMCDDA
- Differences between native and immigrant people who inject drugs using low threshold agencies in Catalonia - Xavier Major Roca, Spain
- High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes - Fernando Vallejo, Spain
- Development and monitoring of needle exchange programme in the Greater Glasgow and Clyde area - Carole Hunter, NHS, Scotland, United Kingdom
Session 8B: National updates of HIV and hepatitis epidemiology and responses in PWID
- Up-to-date surveillance data (HIV notifications), changes in prevalence and responses - Anastasios Fotiou, Greece
- Overview and national update - Lavinius Sava, Romania
- Overview and national update - Igor Condrat, Moldova
- Results of the pilot sero-behavioural study (HIV, HCV) in Warsaw with a comment on the response at national level - Marta Struzik, Poland
Session 9: New threats, new injectors /NPS, new patterns of injecting: public health implications
- The use of crystal methamphetamine, GHB/GBL and mephedrone in sexual settings among gay men in London - Adam Bourne, United Kingdom
- Men who have sex with men and injecting drug use in Paris - Gregory Pfau, France
- Injection, infection, fatalities: NPS situation update for Hungary - Gergely Horváth, Hungary
- Injection NPS challenging for response in Poland - Artur Malczewski, Poland
- HIV outbreak related to injection of new psychoactive substances in Tel Aviv - Haim Mell, Israel
Session 10: Decreasing prevalence/changes of drug injecting and possible effects on service provision
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>
Contact
The EMCDDA is located at:
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
